Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...

Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaApproval based on global phase 3 program ...

The attacks in this case are intense and are the worst kind that an asthmatic patient goes through. In this stage, oxygen supply to the patient is a must. Nasal spikes should be provided to the person ...

Please provide your email address to receive an email when new articles are posted on . Bronchial thermoplasty uses thermal energy to reduce bronchial hyperreactivity and airway inflammation. The ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients with severe asthma experienced decreased ...

Sanofi and Regeneron receives Japanese marketing approval for Dupixent to treat bronchial asthma in children aged 6 to 11 years: Paris Wednesday, December 24, 2025, 11:00 Hrs [IST ...

Are you aware of this condition called "Cardiac Asthma"? It is often confused with asthma, but cardiac asthma is different from bronchial asthma. However, cardiac asthma and bronchial asthma share ...

The Department of Health (DOH) on Friday reported 127 cases of noncommunicable diseases (NCDs) monitored since the holiday ...

Paris: Sanofi and Regeneron have announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and ...